Cure Arthritis Naturally

Cure Arthritis Naturally

Get Instant Access

Askling J, et al. (2005) Risk and case characteristics oftubercu-losis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52(7): 1986-1992

Baert F, et al. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348(7):601 -608 Candon S, et al. (2006) Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol 118(1):11 -19 Centocor BV, Product Information (EU) [online] (2006) Available from URL: [accessed July 2006] Cornillie F, et al. (2001) Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 15(4):463-473 Gottlieb AB, et al. (2003) Pharmacodynamic andpharmacoki-netic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 48(1):68 - 75 Gottlieb AB, et al. (2004) Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51(4):534-542

Hanauer SB, et al. (2004) Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2(7):542-553

Johansen C, et al. (2006) Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol 176(3): 1431 -1438 Kavanaugh A, et al. (2000) Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 27(4):841 - 850 Knight DM, et al. (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30(16):1443 -1453

Lichtenstein GR, et al. (2006) Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 4(5):621 -630 Lipsky PE, et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343(22):1594-1602 Maini RN, et al. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41(9):1552-1563

Maini R, et al. (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354(9194):1932-1939 Markham A, Lamb HM (2000) Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 59(6): 1341-1359

Raddatz D, Bockemuhl M, Ramadori G (2005) Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol 17(5):547-557 Reich K, et al. (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multi-centre, double-blind trial. Lancet 366(9494):1367-1374 Rojas JR, et al. (2005) Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther 313(2): 578-585

Rutgeerts P, et al. (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117(4): 761 - 769

Rutgeerts P, et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353(23): 2462-2476

Sands BE, et al. (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350(9):876-885 Scallon BJ, et al. (1995) Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7(3):251 -259

Scallon B, et al. (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301(2):418-426 St Clair EW, et al. (2002) The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(6):1451 -1459 St Clair EW, et al. (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50(11):3432-3443 Targan SR, et al. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337(15):1029-1035 ten Hove T, et al. (2002) Infliximab treatment induces apopto-sis of lamina propria T lymphocytes in Crohn's disease. Gut 50(2):206-211

Westhovens R, et al. (2006) The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 54(4):1075-1086

Wolbink GJ, et al. (2006) Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54(3):711 -715 Wolfe F, Caplan L, Michaud K (2006) Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheu-matic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 54(2):628-634

Was this article helpful?

0 0
Arthritis Joint Pain

Arthritis Joint Pain

Arthritis is a general term which is commonly associated with a number of painful conditions affecting the joints and bones. The term arthritis literally translates to joint inflammation.

Get My Free Ebook

Post a comment